| |
Move beyond a single set of forecast numbers and embrace uncertainty in healthcare forecasting: IQVIA’s Forecast Horizon is enabling pharma to broaden their analysis and drive deeper insights. Learn more. 
|
|
Today's Big NewsOct 7, 2022 |
|
From generating evidence of treatment safety & efficacy to label expansion, clinical trial tokenization unlocks the value of integrated evidence for teams across the enterprise. Download the eBook to learn how. 
|
|
| By Fraiser Kansteiner There are rumblings of a leadership sea change at Biogen, which Stat News reports is strongly considering Theravance co-founder and former J&J R&D head Mathai Mammen, M.D., Ph.D., in its hunt for a new CEO. |
|
|
|
By Nick Paul Taylor The allogeneic CAR-T cell therapy space is set for its biggest test yet. After ironing out the protocol with the FDA, Allogene Therapeutics has kicked off the first phase 2 clinical trial of an off-the-shelf candidate, setting it up to show how its CD19-directed prospect fares in a potentially pivotal study. |
By Dave Muoio The industry added 60,100 jobs last month with hospitals and ambulatory care picking up about 28,000 each. However, the "pleasant surprise" is tempered by slower growth among nursing and residential care facilities as well as economywide dips in unemployment and labor force participation. |
By Andrea Park NovaSight has scoped out a new, fully digital approach that may be just as effective as wearing an eye patch in treating children—without the discomfort and self-esteem issues that have been linked to wearing eye patches for long periods of time. |
By Angus Liu Just like how the Avengers have repeatedly kept the world safe from Ultron, people need to protect themselves by updating COVID-19 vaccination with the latest booster. That’s the message Pfizer and BioNTech are trying to get across in a new comic book partnered with Marvel. |
By James Waldron When it comes to the current wave of layoffs, smaller biotechs have been disproportionately affected. But even some large drugmakers have been looking to lower their headcount, and now BioMarin is saying goodbye to 120 employees. |
By Anastassia Gliadkovskaya This month, the PA-based plan and Mark Cuban's drug company will begin to let members and community organizations know about their collaboration and how they can access low-cost drugs. Members will be able to use their insurance cards at the pharmacy in 2023. |
By Andrea Park Three months after Dave Scott announced his sudden departure from the helm of Hyperfine—after he’d spent just one year in the position—the portable MRI machine maker has found a new leader. |
By Max Bayer Salvation may be on the horizon for Nektar Therapeutics, months after persistent clinical losses resulted in the end of its multi-billion-dollar deal with Bristol Myers Squibb and significant layoffs. |
By Zoey Becker Amid low demand for its latecomer COVID-19 vaccine, Novavax will pay Fujifilm up to $185 million in quarterly payments to end a supply deal. |
By Gabrielle Masson Long-time PharmaCyte CEO Kenneth Waggoner has departed the biotech, leaving amid a cost freeze on all programs and an ongoing clinical hold on its “Cell-in-a-Box” technology. |
By Conor Hale In under a minute, an artificial intelligence program can take a picture of the back of a person’s eye and—by analyzing the strength of the blood vessels that feed the retina—find clues that may point to higher risks of a stroke or heart attack. |
By Annie Burky CommonSpirit Health is managing an IT security incident affecting some of its facilities in multiple regions including Nebraska, Tennessee and Washington state. The number of facilities affected is still undisclosed as is the security of patient data following the incident which reportedly began Monday. |
By Teresa Carey This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery. 
|
|
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
